Filing Analysis
Lunai Bioworks Inc. filed an 8-K to report the issuance of a letter to shareholders and a corresponding press release on June 17, 2026. The company indicated that the information in this letter may be used in future presentations to investors and partners.
📋 Key Facts
- The filing date is June 17, 2026.
- The company issued a letter to shareholders and a press release on the same day.
- The materials are available on the company's investor relations website (ir.lunaibioworks.com).
- The filing was signed by CEO David Weinstein.
Lunai Bioworks has regained compliance with Nasdaq's minimum bid price rule ($1.00 per share) as of June 11, 2026. However, the company is now subject to a mandatory one-year Panel monitor period.
🚩 Red Flags
- Strict 'no-cure' period: The company is denied the standard compliance grace periods if it fails the bid price rule during the one-year monitoring window.
- History of non-compliance: The filing references previous extension letters from April 20, 2026, and May 12, 2026, indicating a prolonged struggle to maintain the minimum bid price.
📋 Key Facts
- Company regained compliance with Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule) on June 11, 2026.
- The company is now subject to a mandatory Panel monitor for one year.
- During the monitoring period, if the company falls below the $1.00 bid price again, it will not be permitted to submit a new plan of compliance or receive additional time to regain compliance.
- Failure to maintain compliance during the monitor period will lead directly to a delisting determination letter, though the company may request a new hearing.
Lunai Bioworks, Inc. (LNAI) filed an 8-K on May 20, 2026 announcing a 1-for-8 reverse stock split of its common stock (par value $0.0001/share), effective 12:01 a.m. ET on May 22, 2026. The stock will begin trading on a split-adjusted basis on Nasdaq Capital Market under the existing symbol "LNAI" with a new CUSIP number (29350E302) starting May 22, 2026. No financial rationale or context was explicitly provided in the filing beyond the press release reference.
🚩 Red Flags
- 1-for-8 reverse split ratio strongly implies prior trading well below Nasdaq's $1.00 minimum bid price threshold, suggesting a Nasdaq compliance deficiency
- No explicit rationale provided in the filing — omission of stated purpose is atypical and may obscure a compliance-driven trigger
- Reverse stock splits in micro-caps frequently precede continued price deterioration post-split as underlying business fundamentals remain unchanged
- No financial data or operational update accompanies the announcement, limiting investor context
- Short notice window: announcement on May 20, effective May 22 — only ~48 hours between announcement and effectiveness
📋 Key Facts
- Reverse stock split ratio: 1-for-8
- Effective date: May 22, 2026 at 12:01 a.m. Eastern Time
- Split-adjusted trading begins: May 22, 2026 at market open on Nasdaq Capital Market
- Trading symbol remains 'LNAI' post-split
- New CUSIP number post-split: 29350E302
- Common stock par value: $0.0001 per share
- Signed by CEO David Weinstein on May 20, 2026
- Company incorporated in Delaware; headquartered in Sacramento, California
- Filed under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits)
Lunai Bioworks stockholders approved a reverse stock split at a ratio between 1-for-3 and 1-for-30 during a special meeting on May 8, 2026. The action is a defensive measure intended to regain compliance with the Nasdaq Bid Price Rule and maintain the company's listing on The Nasdaq Capital Market.
🚩 Red Flags
- Reverse stock split (often a sign of share price distress in micro-caps).
- Non-compliance with Nasdaq minimum bid price requirements.
- Existence of a Mandatory Panel Monitor, suggesting previous or ongoing listing deficiencies.
📋 Key Facts
- Stockholders approved a reverse stock split ratio ranging from 1-for-3 to 1-for-30.
- The proposal received 13,571,288 votes in favor and 1,153,415 votes against.
- The board of directors has sole discretion to determine the final exact ratio within the approved range.
- The filing explicitly mentions the need to satisfy the Nasdaq 'Bid Price Rule'.
- Reference is made to a 'Mandatory Panel Monitor', indicating the company is under heightened Nasdaq scrutiny.
Lunai Bioworks received a formal notification from Nasdaq that its failure to meet the $35 million Market Value of Listed Securities (MVLS) requirement may serve as a basis for delisting. The company is attempting to regain compliance through a combination of a recent merger to satisfy equity requirements and a pending reverse stock split to satisfy bid price requirements.
🚩 Red Flags
- Formal delisting notice from Nasdaq based on MVLS deficiency.
- Reverse stock split approved (1-for-3 to 1-for-30), which is a high-severity red flag for micro-cap stability.
- Multiple listing deficiencies occurring simultaneously: MVLS, Equity, and Bid Price rules.
- Reliance on a 'short extension' from the Panel to avoid immediate delisting.
📋 Key Facts
- Received Nasdaq staff determination letter on April 28, 2026, regarding non-compliance with Listing Rule 5550(b)(2) (MVLS requirement of $35M).
- Completed a merger on May 1, 2026, issuing Series B Preferred Stock with an aggregate stated value of $20,000,000 to satisfy the $2.5 million stockholders' equity rule.
- Stockholders approved a reverse stock split on May 8, 2026, with a ratio range of 1-for-3 to 1-for-30 to address the Bid Price Rule.
- The company has requested a short extension from the Nasdaq Hearings Panel to evidence compliance with the Bid Price Rule by June 1, 2026.
Lunai Bioworks acquired Neurobridge IP Holdings, a company holding a patent portfolio for Alzheimer's and Parkinson's treatments, from Oncotelic Inc. and Pelerin Therapeutics. The $20 million acquisition was settled entirely through the issuance of Series B Convertible Preferred Stock, which is convertible into common stock at $1.50 per share subject to shareholder approval.
🚩 Red Flags
- Significant potential dilution of approximately 13.3 million shares for a micro-cap company.
- The acquisition involves a shell entity (Neurobridge) with no operational history or revenue.
- Complex 'IP Clawback' and forfeiture provisions (Section 6.9) indicate potential risks regarding the validity or enforceability of the acquired patents.
📋 Key Facts
- Acquisition completed on May 1, 2026, via a triangular merger with a wholly owned subsidiary.
- Total consideration is $20,000,000 in newly designated Series B Convertible Preferred Stock (8 shares total).
- The acquired assets consist solely of a patent portfolio; Neurobridge had no revenue, employees, or operating infrastructure.
- The conversion price is fixed at $1.50 per share, representing a maximum of 13,333,333 underlying common shares.
- Conversion is contingent upon stockholder approval under Nasdaq Listing Rule 5635.
- The patent portfolio includes treatments for Alzheimer's disease and anti-TGF-beta agents for neurological disorders like Parkinson's.
Lunai Bioworks postponed its Special Meeting of Stockholders from May 4 to May 8, 2026, to allow more time for proxy voting and to satisfy NYSE Rule 452 requirements for broker discretionary voting. The meeting's primary purpose is to vote on a proposed reverse stock split intended to maintain Nasdaq listing compliance.
🚩 Red Flags
- Proposed reverse stock split, typically used to address Nasdaq minimum bid price deficiencies.
- Postponement of a shareholder meeting due to concerns about obtaining a quorum or sufficient votes.
- Explicit mention of the risk of delisting from The Nasdaq Stock Market LLC.
📋 Key Facts
- Special Meeting postponed from May 4, 2026, to May 8, 2026, at 9:00 a.m. ET.
- The meeting will consider a Reverse Stock Split Proposal and an Adjournment Proposal.
- Postponement is intended to assist the Company in obtaining a quorum and to allow brokers to exercise discretionary voting authority under NYSE Rule 452.
- Broadridge Financial Solutions distributed proxy materials on April 22, 2026.
- The record date for stockholders entitled to vote remains April 10, 2026.
Lunai Bioworks announced a $20 million strategic acquisition of Alzheimer's drug assets and blood-brain barrier technology from Clemann Group, alongside a debt-for-equity exchange to extinguish approximately $829,000 in secured debt.
🚩 Red Flags
- Multiple 8-K items reported in a single filing (1.01, 3.02, 8.01).
- Significant dilution from debt exchange at a low price of $0.21 per share.
- The extinguished debt was 'secured,' indicating the company was previously under restrictive financing terms.
- Large discrepancy between the debt exchange price ($0.21) and the new Series B conversion price ($1.50).
📋 Key Facts
- Entered into Debt Exchange Agreements on March 24, 2026, to cancel $828,770.14 of outstanding principal and interest.
- Issued 3,909,293 shares and 1,433,621 warrants in the debt exchange at an implied price of $0.21 per share.
- Entered into a binding agreement on March 26, 2026, to acquire blood-brain barrier delivery technology and CNS Alzheimer's drug assets from Clemann Group.
- The acquisition is structured as a $20.0 million strategic investment in Series B Convertible Preferred Stock with a fixed conversion price of $1.50 per share.
- The debt exchange will result in the release of security interests under an Amended and Restated Security Agreement dated January 2, 2024.
- The Series B Preferred Stock includes a 19.9% beneficial ownership limitation and no variable pricing or reset provisions.
Lunai Bioworks Inc. implemented a temporary furlough of its workforce in the United States and Canada on February 27, 2026, to preserve liquidity. The company's CEO and CFO have also voluntarily deferred their salaries while the firm seeks additional financing to sustain operations.
🚩 Red Flags
- Extreme liquidity crisis necessitating a total workforce furlough.
- Executive salary deferral indicates a lack of immediate cash reserves.
- Uncertainty regarding the company's ability to continue as a going concern without immediate financing.
- Operational disruption that may impact long-term platform development and contractual obligations.
📋 Key Facts
- Furlough of U.S. and Canadian employees commenced on February 27, 2026.
- CEO David Weinstein and the CFO have deferred their salary payments.
- The company is operating at limited capacity and attempting to secure additional capital.
- The duration of the furlough is indefinite and dependent on the success of capital-raising efforts.
- Some operational employees have been recalled to support platform development.
Lunai Bioworks Inc. (LNAI) received a formal delisting determination letter from Nasdaq Listing Qualifications Staff on February 6, 2026. The Company has appealed the decision and secured a hearing before the Nasdaq Hearings Panel scheduled for March 26, 2026, with the delisting action stayed pending the Panel's final written decision. No assurance is provided that the Company will retain its Nasdaq listing or maintain compliance with continued listing requirements.
🚩 Red Flags
- Nasdaq Staff has already made a formal determination to delist LNAI — this is beyond a mere compliance warning notice.
- The Company provides no assurance of continued listing, signaling weak confidence in a favorable Panel outcome.
- The underlying compliance deficiency triggering the delisting determination has not been disclosed in this filing, obscuring the root cause and severity.
- A March 26, 2026 hearing date means the listing uncertainty will persist for over a month, creating prolonged investor risk.
- Delisting from Nasdaq would likely force trading to OTC markets, severely reducing liquidity and institutional investor access for a micro-cap company.
📋 Key Facts
- On February 6, 2026, Nasdaq Listing Qualifications Staff issued a formal determination letter to delist LNAI's securities from The Nasdaq Stock Market LLC.
- The Company timely requested a hearing before the Nasdaq Hearings Panel (the 'Panel') to appeal the Staff's delisting determination.
- On February 17, 2026 (the event date of this 8-K), Nasdaq notified the Company that the Panel granted the hearing request.
- The hearing has been scheduled for March 26, 2026.
- The delisting action has been stayed pending a final written decision by the Panel.
- The Company explicitly disclaims any assurance that the Panel will grant continued listing or that compliance with Nasdaq requirements can be maintained.
- The 8-K was filed February 23, 2026, and signed by CEO David Weinstein.
- LNAI is listed under Commission File Number 001-38751, incorporated in Delaware, headquartered in Sacramento, California.
- Common Stock trades under ticker LNAI on Nasdaq with par value $0.0001 per share.
Lunai Bioworks received a notice from Nasdaq stating its securities are subject to delisting for failing to maintain a minimum bid price of $1.00 per share. The company is ineligible for the standard 180-day compliance period because it executed a 1-for-10 reverse stock split on September 30, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq
- Ineligibility for compliance period due to recent reverse stock split (Red Flag Escalator)
- Stock price failure to maintain $1.00 minimum bid requirement
📋 Key Facts
- Nasdaq determined non-compliance with Listing Rule 5550(a)(2) after the bid price closed below $1.00 for 30 consecutive business days (Dec 23, 2025 – Feb 5, 2026).
- The company is ineligible for a compliance period due to a 1-for-10 reverse stock split performed on September 30, 2025.
- Trading suspension is scheduled for February 18, 2026, unless an appeal is successful.
- The Company has filed a request for a hearing before the Nasdaq Hearings Panel to stay the delisting process.
Lunai Bioworks, Inc. entered into an At-the-Market (ATM) sales agreement with Dawson James Securities, Inc. to offer and sell up to $11.70 million of its common stock.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of new common stock.
- ATM offerings are often used by micro-cap companies to bolster immediate liquidity, which can signal cash runway concerns.
📋 Key Facts
- Entered into an At-the-Market Sales Agreement on December 2, 2025.
- The offering has an aggregate price limit of up to $11.70 million.
- Sales Agent: Dawson James Securities, Inc.
- Agent compensation is set at 3.0% of gross proceeds.
- Shares will be sold under a previously declared effective Form S-3 registration statement (File No. 333-282898) dated November 6, 2024.
Lunai Bioworks Inc. entered into a securities purchase agreement on November 24, 2025, to conduct a private placement of common stock and warrants to an accredited investor.
🚩 Red Flags
- Potential dilution for existing shareholders due to issuance of over 3 million new shares and 1 million warrants.
- Warrants are executable in 60 days, which may lead to further immediate dilution.
📋 Key Facts
- Date of Agreement: November 24, 2025
- Total Gross Proceeds: $3,133,333
- Common Shares Issued: 3,133,333 shares at $1.00 per share
- Warrants Issued: 1,044,444 three-year warrants
- Warrant Terms: Executable after sixty (60) days
- Exemption: Reliance on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D
Lunai Bioworks Inc. reports that it has resolved a non-compliance notice from Nasdaq regarding the timing of its annual shareholder meeting. Following an annual meeting held on October 31, 2025, the company is now back in compliance with Nasdaq Listing Rule 5620(a).
🚩 Red Flags
- Previous non-compliance with Nasdaq listing rules (though now resolved).
📋 Key Facts
- Received a written notice from Nasdaq on July 7, 2025, regarding non-compliance with Nasdaq Listing Rule 5620(a).
- The violation pertained to the requirement to hold an annual meeting of shareholders within one year of fiscal year-end.
- An annual meeting was successfully held on October 31, 2025.
- Nasdaq has officially closed the matter and confirmed the company is in compliance.
Lunai Bioworks Inc. held its annual meeting of shareholders on October 31, 2025. Shareholders approved all four proposals, including the election of directors, Say-on-Pay, auditor ratification, and amendments to the equity incentive plan.
📋 Key Facts
- Annual Meeting held on October 31, 2025.
- Four director nominees elected: David Weinstein, James McNulty, Douglas W. Calder, and Mark A. Collins.
- Shareholders approved 'Say-on-Pay' advisory vote regarding executive compensation (5,548,091 For vs. 2,182,131 Against).
- Sadler, Gibb & Associates LLC was ratified as the independent registered public accounting firm for fiscal year ending June 30, 2026.
- Amendments to the Renovaro Biosciences, Inc. 2023 Equity Incentive Plan were approved.
Lunai Bioworks received a notice from Nasdaq stating it is non-compliant with the $35 million minimum Market Value of Listed Securities (MVLS) requirement. The company has 180 days, until April 27, 2026, to regain compliance by maintaining an MVLS of at least $35 million for 10 consecutive business days.
🚩 Red Flags
- Delisting notice (Nasdaq Rule 5550(b)(2))
- Failure to meet minimum market value requirements indicates significant loss in shareholder equity or market capitalization.
- Potential for delisting if compliance is not met by April 27, 2026.
📋 Key Facts
- Received Nasdaq notification on October 27, 2025.
- Non-compliance is due to the Market Value of Listed Securities (MVLS) being below $35 million for the previous 30 consecutive business days.
- Compliance period extends until April 27, 2026.
- To cure deficiency: MVLS must close at $35M+ for 10 consecutive business days during the compliance window.
- Trading continues on Nasdaq Capital Market under symbol LNAI.
Lunai Bioworks Inc. has regained compliance with NASDAQ's minimum bid price requirement (Listing Rule 5550(a)(2)). The company successfully maintained a closing bid price of $1.00 or greater for eleven consecutive business days.
🚩 Red Flags
- History of delisting risk due to low stock price (minimum $1.00 requirement).
📋 Key Facts
- The Company received notice from NASDAQ on October 15, 2025, regarding compliance with Listing Rule 5550(a)(2).
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for eleven consecutive business days (Sept 30, 2025 – Oct 14, 2025).
- The company had previously been notified of failure to maintain the minimum bid price on April 14, 2025.
Lunai Bioworks, Inc. has announced a 1-for-10 reverse stock split effective September 29, 2025. The move is intended to consolidate shares and will result in the common stock trading on a split-adjusted basis on Nasdaq starting September 30, 2025.
🚩 Red Flags
- Reverse stock split (often used to avoid Nasdaq delisting due to minimum bid price requirements)
- Significant reduction in share count which can be a sign of capital restructuring/distress
📋 Key Facts
- Reverse stock split ratio: 1-for-10
- Effective date of split: 12:01 a.m. ET on September 29, 2025
- Trading resumes on a split-adjusted basis: September 30, 2025
- Expected reduction in shares outstanding from ~231.78 million to ~23.18 million
- No fractional shares will be issued; fractions rounded up to the next whole share
- Authorized shares remain unchanged at 350,000,000
- New CUSIP number: 29350E 203
Lunai Bioworks Inc. announced that its indirect subsidiary, Gedi Cube B.V., has been declared bankrupt by the Court of Amsterdam due to an inability to meet payment obligations. The company expects a material impairment charge related to this event in the upcoming Q3 2025 financial results.
🚩 Red Flags
- Bankruptcy of an indirect subsidiary (Gedi Cube B.V.).
- Material asset impairment expected for Q3 2025.
- Potential disruption to supply chain and customer relationships due to the subsidiary's insolvency.
- Management is currently unable to estimate the specific cash expenditures or total amount of the impairment charge.
📋 Key Facts
- Gedi Cube B.V., an indirect subsidiary of Lunai Bioworks, filed for voluntary bankruptcy.
- The Court of Amsterdam declared Gedi bankrupt on September 2, 2025.
- Mr. M.M. Dellebeke has been appointed as the receiver for Gedi.
- Lunai Bioworks and its other subsidiaries are not filing for bankruptcy and will continue normal operations.
- Management expects to record a material impairment charge in the quarter ending September 30, 2025.
Renovaro Inc. has officially changed its corporate name to Lunai Bioworks Inc., effective August 20, 2025. The company will continue trading on the Nasdaq under the ticker symbol RENB.
🚩 Red Flags
- Forward-looking statements mention plans to 'regain compliance with Nasdaq listing standards,' implying current non-compliance or risk of delisting.
📋 Key Facts
- Corporate name changed from 'Renovaro Inc.' to 'Lunai Bioworks Inc.'
- Name change became effective on August 20, 2025.
- The company will continue to trade on the Nasdaq under the ticker symbol RENB.
- A new CUSIP number for the common stock will be issued as a result of the name change.
Renovaro Inc. received a notice from Nasdaq for failing to comply with Rule 5620(a) regarding the requirement to hold an annual meeting of shareholders. The company has been granted an extension until October 31, 2025, to hold the meeting and regain compliance.
🚩 Red Flags
- Delisting notice/non-compliance with Nasdaq listing rules.
- Failure to meet administrative governance requirements (annual meeting).
📋 Key Facts
- Received notice from Nasdaq on July 7, 2025, for non-compliance with Listing Rule 5620(a).
- Rule 5620(a) requires companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year.
- Nasdaq accepted a compliance plan on August 5, 2025.
- The company has been granted an extension until October 31, 2025, to hold its annual meeting.
Renovaro Inc. announced the resignation of Maurice van Tilburg from his position as Chairman of the Board, effective August 22, 2025. The departure is attributed to a new leadership role in an unrelated sector and not due to any disagreements with the company.
📋 Key Facts
- Maurice van Tilburg resigned as Chairman of the Board on July 22, 2025.
- The resignation becomes effective on August 22, 2025.
- Reason for departure: Acceptance of a leadership position at another company in an unrelated sector.
- Company states there were no disagreements regarding operations, policies, or practices.
Renovaro Inc. received a notice from Nasdaq stating it is in non-compliance with Listing Rule 5620(a) due to failure to hold an annual meeting of shareholders within the required timeframe. The company has 45 days to submit a compliance plan to avoid potential delisting.
🚩 Red Flags
- Delisting notice (Nasdaq non-compliance)
- Failure to meet basic corporate governance standards (annual meeting requirement)
📋 Key Facts
- Received written notice from Nasdaq on July 7, 2025.
- Non-compliance stems from failure to hold an annual meeting of shareholders within 12 months of the fiscal year ended June 30, 2024.
- The company has 45 calendar days from the notice date to submit a plan to regain compliance.
- If a plan is accepted, Nasdaq may grant an extension until December 29, 2025, to satisfy requirements.
Renovaro Inc. restructured $9.7 million in secured debt into $16.1 million in convertible notes, which were immediately converted into 53.6 million shares of common stock at $0.30 per share. This transaction resulted in massive equity dilution for existing shareholders without providing any new cash to the company.
🚩 Red Flags
- Massive equity dilution: Issuance of 53.6 million new shares significantly dilutes existing shareholders.
- Debt-for-equity swap: Indicates the company is using its equity to settle obligations rather than cash, often a sign of liquidity constraints.
- Extremely short maturity: The convertible notes were set to mature on July 31, 2025 (only 24 days after issuance), forcing immediate conversion and dilution.
- Lack of cash inflow: Despite restructuring $9.7M in debt, the company received no new capital to fund operations.
📋 Key Facts
- Exchanged $9.7M in secured promissory notes for $16.1M in non-interest-bearing convertible notes on July 7, 2025.
- The conversion price was set at $0.30 per share, representing a 65% premium to the principal/interest of the original debt.
- Investors immediately converted the full $16.1M into 53.6 million shares of common stock.
- The transaction resulted in zero net cash proceeds to the company.
- Shares are expected to be issued on or before July 11, 2025.
Maurice van Tilburg has resigned from his position as CEO of GEDi Cube B.V., a wholly-owned indirect subsidiary of Renovaro Inc., effective May 30, 2025. The resignation is not due to any disagreement with the Company or its Board.
📋 Key Facts
- Maurice van Tilburg resigned as CEO of GEDi Cube B.V. on May 30, 2025.
- The resignation was not due to any disagreements regarding operations, policies, or practices.
- Mr. van Tilburg will remain a member of the Company's Board of Directors.
Renovaro Inc. received a deficiency notice from Nasdaq because its common stock failed to maintain the $1 minimum bid price requirement for 30 consecutive business days. The company has an initial 180-day period to regain compliance by October 13, 2025.
🚩 Red Flags
- Delisting notice (Nasdaq non-compliance)
- Failure to maintain minimum bid price requirement ($1.00 threshold)
📋 Key Facts
- Received deficiency notice from Nasdaq on April 14, 2025.
- Failure to comply with Nasdaq Listing Rule 5550(a)(2) regarding the $1 minimum bid price requirement.
- Initial compliance period expires October 13, 2025.
- To regain compliance, stock must close at or above $1.00 for 10 consecutive business days within the window.
- A second 180-day extension may be available if certain market value and public share requirements are met.
Renovaro Inc. has consummated its merger with Biosymetrics, Inc., resulting in the issuance of 15.0 million shares of common stock to former stockholders of Biosymetrics.
🚩 Red Flags
- Significant dilution: Issuance of 15.0 million new shares significantly increases the share count, likely diluting existing shareholders.
📋 Key Facts
- Transaction consummated on April 8, 2025.
- Issuance of 15.0 million shares of Renovaro's common stock ($0.0001 par value).
- Biosymetrics, Inc. will become a wholly owned subsidiary of Renovaro.
- The issuance was made in reliance on Section 4(a)(2) exemption from registration requirements.
- Issuance targeted at 'accredited investors' as defined under Rule 501(a).
Renovaro Inc. has entered into an extension agreement to amend its existing Letter of Intent (LOI) with Predictive Oncology Inc. regarding a proposed acquisition. The amendment extends the termination date to March 31, 2025, and includes new provisions for share purchases.
🚩 Red Flags
- Extension of LOI suggests negotiations are ongoing and the deal has not yet reached definitive terms or closing certainty.
- Transaction relies on future execution of a definitive agreement, which remains subject to various risks including stockholder approval.
📋 Key Facts
- The LOI expiration date has been extended from February 28, 2025, to March 31, 2025.
- Renovaro acquired 467,290 shares of Predictive Oncology common stock for $500,000 on February 28, 2025.
- Renovaro agreed to purchase an additional 901,298 shares of Predictive Oncology common stock for $964,389 upon execution of a definitive agreement.
- The proposed transaction involves the acquisition of all capital stock of Predictive Oncology by Renovaro via a Form S-4 registration statement.
Renovaro Inc. has entered into a definitive merger agreement to acquire Biosymetrics, Inc., an AI-driven drug discovery company, via a reverse takeover structure where Biosymetrics will become a wholly owned subsidiary.
🚩 Red Flags
- Significant dilution: The issuance of 15 million new shares will significantly impact existing shareholders' ownership percentage.
- Unregistered securities: The shares are being issued in a private placement (Section 4(a)(2)) and are not immediately freely tradable.
- Short timeline: The merger must close by March 15, 2025, leaving a very narrow window for closing conditions to be met.
📋 Key Facts
- Entered into Merger Agreement on February 26, 2025.
- Biosymetrics stockholders to receive 15 million shares of Renovaro common stock in exchange for all outstanding shares.
- The transaction involves the issuance of unregistered equity securities under Section 4(a)(2) of the Securities Act.
- A one-year lock-up period applies to the CEO/majority stockholder of Biosymetrics regarding the received shares.
- Three million of the issued shares are subject to a one-year escrow requirement.
- The transaction is subject to Biosymetrics stockholder approval and Nasdaq listing requirements for the new shares.
- Termination deadline set for March 15, 2025, if not closed.
Renovaro Inc. has determined that its previously issued financial statements for the period ending June 30, 2024, and certain quarterly reports in 2024 and early 2025, contain material misstatements. The error stems from failing to properly account for warrant exercises as a component of changes in fair value for contingent consideration.
🚩 Red Flags
- Material misstatement identified in multiple prior filings (10-K and 10-Qs).
- Non-reliance on previously issued audited and unaudited financial statements.
- Potential for significant adjustments to equity or liability accounts due to contingent consideration errors.
📋 Key Facts
- The Audit Committee concluded that prior financial statements should no longer be relied upon.
- Affected filings include: Q3 2024 Form 10-Q, FY 2024 Form 10-K, and Q1 2025 Form 10-Q.
- The error relates to the treatment of warrants exercised during the three months ended March 31, 2024.
- Misstatements involve the failure to reflect warrant exercises as a component of the change in fair value of contingent consideration.
- The company intends to restate the affected filings as soon as reasonably practicable.
Renovaro Inc. announced an amended and restated employment agreement for Maurice van Tilburg in his capacity as CEO of GEDi Cube B.V., a wholly owned subsidiary.
🚩 Red Flags
- Complexity of corporate structure: The CEO is an officer of a subsidiary (GEDi Cube B.V.) rather than the parent company directly, which can sometimes obscure direct compensation oversight in micro-cap entities.
📋 Key Facts
- Effective date of the amended agreement: February 4, 2025.
- Maurice van Tilburg serves as CEO of GEDi Cube B.V. (a subsidiary).
- Monthly salary for Mr. van Tilburg is €22,080 (~$22,806).
- Annual performance bonus potential up to €96,000 (~$99,158).
- Compensation includes participation in a share option plan and a collective pension plan administered by A.S.R. Nederland.
- The agreement supplements the previous employment agreement disclosed on January 6, 2025.
Renovaro Inc. announced the appointment of Nathen Fuentes as Chief Financial Officer, effective January 6, 2025. This transition involves the removal of Simon Tarsh from his role as Interim CFO.
🚩 Red Flags
- Removal of an interim officer often signals a transition period, though common during permanent hires.
📋 Key Facts
- Nathen Fuentes appointed as CFO effective January 6, 2025.
- Fuentes' base salary is set at $280,000 per year with a performance bonus up to $40,000.
- Equity incentive grant of 250,000 stock options vesting ratably over eight quarters.
- Severance package includes 6 months of base salary and accelerated vesting if terminated without cause or for good reason.
- Simon Tarsh removed as Interim CFO in connection with the new appointment.
Renovaro Inc. has entered into a binding letter of intent to acquire Predictive Oncology Inc. (NASDAQ: POAI) through a merger involving the issuance of preferred stock. The deal is contingent upon Renovaro raising at least $15 million and obtaining shareholder approval from Predictive Oncology.
🚩 Red Flags
- High dependency on successful $15 million fundraising to close the deal.
- Potential dilutive impact via the issuance of preferred stock convertible to common equity.
- Redemption clause at $3.00 per share creates a floor/liability that may pressure cash reserves if stock price remains low.
📋 Key Facts
- Binding Letter of Intent signed on January 6, 2025, for the acquisition of Predictive Oncology Inc. (POAI).
- Transaction structure: POAI shareholders to receive a newly created series of Renovaro preferred stock in a 1:1 exchange for existing common stock.
- Preferred stock features: Automatically redeemable for $3.00 per share after 18 months; convertible to Renovaro common stock (1:1 ratio) if Renovaro stock trades at or above $4.50 for 30 consecutive days.
- Redemption right: Renovaro can redeem preferred stock for $3.00 cash if stock price is $€3.00 or less, or if conversion is not requested within 30 days of eligibility.
- Contingent liability: If POAI warrants are not exercised by Jan 15, 2025, Renovaro must purchase up to 2.33 million shares at $1.07 per share.
- Condition precedent: The merger is subject to a minimum fundraising of $15 million by Renovaro.
- Contingent asset acquisition: If shareholder approval fails under certain capital conditions, Renovaro gains a two-year exclusive royalty-free license to POAI's biobank and 3D cell culture models.
Renovaro Inc. announced the appointment of Maurice van Tilburg as CEO of GEDi Cube B.V., a wholly owned subsidiary. The appointment includes a significant equity incentive package and a base salary of $300,000.
🚩 Red Flags
- Significant dilution potential via 250,000 sign-on shares and 1,000,000 stock options for a subsidiary CEO.
📋 Key Facts
- Maurice van Tilburg appointed CEO of GEDi Cube B.V. effective December 30, 2024.
- Base salary set at $300,000 per year with a performance bonus potential of up to $100,000 annually.
- Compensation includes a sign-on bonus of 250,000 shares of restricted common stock and an equity incentive grant of 1,000,000 stock options vesting over five years.
- Van Tilburg previously served as CEO of Euronext Amsterdam and currently serves on the Board.
Renovaro Inc. announced the resignation of its Chief Operating Officer, Francois Binette PhD, effective November 22, 2024.
📋 Key Facts
- Francois Binette PhD resigned from his position as Chief Operating Officer.
- The resignation was tendered on November 15, 2024.
- The effective date of the departure is November 22, 2024.
Renovaro Inc. has entered into an amended and restated consulting agreement with Tarsh PB Advisors regarding Simon Tarsh's service as Interim Chief Financial Officer, effective November 4, 2024.
🚩 Red Flags
- High monthly cash burn for interim services ($25,000/month plus bonuses).
- Significant equity incentive (58,500 options) tied to the termination of the interim role, which may create misalignment in seeking a permanent replacement.
- Use of an advisory firm (Tarsh PB Advisors) rather than a direct employee for the CFO role often indicates liquidity constraints or rapid turnover.
📋 Key Facts
- The company will pay Tarsh PB Advisors $25,000 per month for full-time services.
- Potential milestone-based payments up to 30% of the total consideration under the agreement.
- Simon Tarsh received a bonus of $29,063 on October 31, 2024, and is scheduled for another $29,063 on November 30, 2024.
- 58,500 stock options will vest upon the termination date if a new CFO is hired before that date.
- The agreement has an initial term of three months with one-month renewal options.
This Form 8-K/A is an amendment to a previous filing, providing supplemental information regarding the committee appointments of four newly appointed directors. The filing clarifies the specific roles these individuals will hold within the company's various board committees.
🚩 Red Flags
- The appointment of a 'Special Litigation Committee' often suggests the company is addressing internal legal disputes or shareholder litigation, which can be a sign of underlying governance issues or pending legal costs.
📋 Key Facts
- Filing date: October 29, 2024 (reporting event date: October 11, 2024).
- Maurice van Tilburg appointed to Nominating and Governance Committee and Special Litigation Committee.
- James A. McNulty appointed as Chair of the Audit Committee; also member of Special Litigation and Compensation Committees.
- Douglas W. Calder appointed to Audit Committee, Nominating and Governance Committee, and Compensation Committee.
- Dr. Mark Collins appointed to Audit Committee and Special Litigation Committee.
- All directors will enter into standard indemnification agreements.
Renovaro Inc. underwent a massive leadership and board overhaul involving the resignation of its CEO, several directors (including the Audit and Compensation Committee chairs), and the appointment of a new CEO and four new directors. The filing indicates a near-total replacement of the company's governance structure.
🚩 Red Flags
- Massive board turnover: Almost the entire previous board and executive leadership resigned simultaneously.
- Resignation of Audit Committee Chair (James Sapirstein) and other key committee members (Alton, McNicol, Brosgart).
- Significant dilution risk via new CEO equity package (1.6M options + 250k restricted stock sign-on + discretionary grants).
📋 Key Facts
- CEO Mark Dybul, M.D., resigned on October 12, 2024.
- David Weinstein appointed as new CEO effective October 14, 2024; includes a $400k base salary and 1.6M stock options vesting over 8 quarters.
- Four new directors appointed: Maurice van Tilburg, James McNulty, Douglas Calder, and Mark Collins.
- Mass resignation of existing board members including Avram Miller, Ruud Hendriks, Karen Brink, James Sapirstein (Audit/Comp Committee), Gregg Alton (Lead Independent Director/Audit Chair), Jayne McNicol (Audit Chair), and Carol Brosgart.
- The resignations were not due to disagreements regarding operations, policies, or practices.
Renovaro Inc. received a deficiency notice from Nasdaq because its common stock failed to meet the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(a)(2))
- Failure to maintain minimum bid price requirement
📋 Key Facts
- Received deficiency notice on September 12, 2024.
- Failure based on the closing bid price being below $1.00 for 30 consecutive business days prior to the notice.
- Initial compliance period granted until March 11, 2025 (180 calendar days).
- To regain compliance, stock must close at or above $1.00 for at least 10 consecutive business days before the deadline.
- Potential for a second 180-day compliance period if market value requirements are met and intent to cure is filed.
Renovaro Inc. announced its intention to seek strategic investors for a sale of up to 20% ownership in its wholly owned subsidiary, RenovaroCube. The proceeds are intended to advance Cube's AI-driven molecular data science platform.
🚩 Red Flags
- The offering is for a subsidiary rather than the parent company, which can lead to complex corporate structures or potential dilution of interest in the core technology if not structured carefully.
📋 Key Facts
- The company intends to sell up to 20% of RenovaroCube, currently a wholly owned subsidiary.
- The offering will be available to all potential investors, including current RENB shareholders.
- Proceeds from the offering are intended to advance Cube's platform and go-to-market strategy.
- RenovaroCube focuses on AI technology for multi-omics and multi-modal data analysis in precision medicine.
- Subscription terms have not yet been determined.
Renovaro Inc. has determined that its unaudited interim financial statements for the quarter ended March 31, 2024, contain material misstatements regarding the valuation of indefinite-life intangible assets (IPR&D) and should no longer be relied upon. The error stems from an incorrect impairment measurement following the termination of a license agreement.
🚩 Red Flags
- Material misstatement in previously issued financial statements (Item 4.02).
- Significant asset impairment related to a terminated license agreement.
- Ongoing litigation involving allegations of fraudulent concealment and a 'murder-for-hire scheme' by former associates/merger parties.
📋 Key Facts
- The company's Audit Committee concluded that March 31, 2024, financial statements contain material misstatements.
- Misstatement relates to the valuation of IPR&D assets and associated non-cash impairment charges.
- The error resulted in an overstatement of assets and an understatement of net loss/net loss per share for the three and nine months ended March 31, 2024.
- The company expects to file amended Form 10-Q during the week of August 19, 2024.
- A license agreement for product candidate RENB-HV-01 was terminated by the licensor.
Renovaro Inc. announced the resignation of Leni Boeren from its Board of Directors, effective June 27, 2024. The departure is attributed to personal family health reasons and not due to any disagreements with management or company practices.
🚩 Red Flags
- Departure of a member who chaired the Special Litigation Committee (SLC) can sometimes signal internal friction, though the filing explicitly denies any disagreement.
📋 Key Facts
- Leni Boeren resigned from the Board of Directors on June 27, 2024.
- The resignation was effective immediately upon notice.
- Ms. Boeren previously served as the chair of the Company's special litigation committee.
- The company explicitly stated the departure is due to family health reasons and not a disagreement regarding management, policies, or practices.
Renovaro Inc. closed a private placement of 6,421,256 units on June 14, 2024, consisting of one share of common stock and one warrant per unit. The offering involved both new cash investment and the conversion/termination of existing convertible promissory notes.
🚩 Red Flags
- Significant portion of the 'offering' is actually a debt-for-equity swap (conversion of promissory notes), which can lead to future dilution.
- Warrants issued alongside common stock create potential dilutive overhang for existing shareholders.
📋 Key Facts
- Closed a private placement of 6,421,256 units on June 14, 2024.
- Each unit includes one share of common stock and one warrant to purchase 0.1 shares at $1.4726 per share.
- Warrants are exercisable for five years from the date of issuance.
- One investor paid $5,801,012 in cash for 3,939,299 units.
- Investors surrendered and terminated $3,654,929 in aggregate principal/interest of convertible promissory notes to acquire 2,481,957 units.
- Total cash received from investors was approximately $5,344,078 ($5,801,012 + $478,059 + $66,000).
- Proceeds are intended for general corporate purposes.
Renovaro Inc. filed an 8-K to announce the Board's approval of amended and restated bylaws effective May 21, 2024. The amendment primarily updates the company's name and officer titles within its corporate governance documents.
📋 Key Facts
- Board approved amendment and restatement of Bylaws on May 21, 2024.
- The update includes a formal change to the Company's name in the bylaws.
- The filing updates various officer titles used throughout the corporate documents.
- Amended and Restated Bylaws were filed as Exhibit 3.1.
Renovaro Inc. filed an 8-K to furnish a press release issued on May 24, 2024. The filing does not contain substantive financial data or material event details within the text provided.
🚩 Red Flags
- Interim CFO role suggests potential management instability or transition (though common in micro-caps).
📋 Key Facts
- The company issued a press release on May 24, 2024.
- The press release is furnished as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 liability.
- Simon Tarsh signed the report in his capacity as Interim Chief Financial Officer.
Renovaro Inc. issued a press release announcing 'Flamingo,' a new AI model developed by its subsidiary RenovaroCube for multi-cancer detection using fragmentomics and ultra-low pass whole genome sequencing (ULP-WGS). The announcement highlights the expansion of the company's 'The Cube' AI/machine learning platform.
📋 Key Facts
- Introduction of 'Flamingo,' an AI model based on fragmentomics for multi-cancer detection.
- Technology utilizes ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA).
- The model uses as few as 200,000 cfDNA fragments per sample to distinguish cancer from healthy samples.
- Flamingo is integrated into 'The Cube,' the company's existing multi-omic AI/machine learning platform.
- Mention of a previously announced acquisition of Cyclomics, which will enhance liquid biopsy capabilities.
Renovaro Inc. filed an 8-K to furnish a press release issued on April 24, 2024. The filing does not contain specific material financial data or structural changes within the text provided.
📋 Key Facts
- The company issued a press release on April 24, 2024.
- The press release is furnished as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 liability.
- The filing was signed by CEO Mark Dybul, M.D. on April 25, 2024.
Renovaro Inc. filed an amendment to its February 8-K to include audited financial statements and pro forma information following the acquisition of Renovaro Cube Intl Ltd. on February 13, 2024.
🚩 Red Flags
- The filing is an amendment (8-K/A) to a previous report, indicating a delay in providing required financial exhibits following the transaction.
📋 Key Facts
- Acquisition closed on February 13, 2024.
- The target company is Renovaro Cube Intl Ltd. (formerly GEDi Cube Intl Ltd.), a private entity formed in England and Wales.
- Filing includes audited financial statements for the years ended December 31, 2023, and 2022.
- Includes unaudited pro forma combined financial information as of December 31, 2023, and for the six months ended December 31, 2023.
Renovaro Inc. announced the appointment of Simon Tarsh as Interim Chief Financial Officer effective March 11, 2024, following the departure of long-term CFO Ms. Puche.
🚩 Red Flags
- Use of a third-party consulting firm (Tarsh PB Advisors LLC) rather than a direct employee for the Interim CFO role.
- Performance-based milestone payments (up to 30%) tied to the interim period.
- Potential conflict/complexity regarding the vesting of stock options upon the hiring of a permanent replacement.
📋 Key Facts
- Simon Tarsh appointed as Interim CFO effective March 11, 2024.
- Tarsh PB Advisors LLC (Mr. Tarsh's consulting firm) entered into a consulting agreement with the Company.
- The Company will pay $25,000 per month for full-time services.
- Potential milestone-based bonus of up to 30% of total consideration paid under the agreement.
- Mr. Tarsh to receive 10,000 stock options vesting upon termination if a permanent CFO is hired before the end of his term.
- The consulting agreement has an initial six-month term with one-month renewal options.
- Outgoing CFO Ms. Puche served for over 5 years and will provide ad hoc consulting during transition.
Renovaro Inc. announced that its subsidiary received a termination notice for a License Agreement with Weird Science LLC regarding the product candidate RENB-HV-01. While the company states it is considering all legal options, this follows a prior deprioritization of the asset due to high costs.
🚩 Red Flags
- Loss of intellectual property/license rights for a product candidate (RENB-HV-01).
- Potential legal dispute or litigation as the company 'is considering all of its options' regarding the termination.
- The loss of a license can impact the long-term valuation and asset base of the company.
📋 Key Facts
- Termination notice received on March 1, 2024, from Weird Science LLC.
- The agreement in question is the License Agreement dated February 16, 2018.
- The affected product candidate is RENB-HV-01 (Autologous Transplant with Genetically Modified Cells).
- RENB-HV-01 had already been deprioritized by the company due to high costs and long development timelines.
- The company's current lead candidate is RENB-DC-11, a potential cancer vaccine for solid tumors.
Renovaro Inc. announced the resignation of its Chief Financial Officer, Luisa Puche, effective March 21, 2024. The company stated the departure is not due to any disagreements with management or the Board and has identified an interim successor.
🚩 Red Flags
- Sudden departure of the CFO (though no disagreement was cited, it remains a key personnel risk for micro-cap companies).
📋 Key Facts
- Luisa Puche resigned as CFO on February 28, 2024.
- The resignation becomes effective March 21, 2024.
- An interim-CFO candidate has already been identified.
- The company is negotiating an overlap period to ensure a smooth transition.
- Ms. Puche may continue in a consulting role if needed.
Renovaro Inc. announced it has received commitments for an additional $3,000,000 in equity financing, which is expected to close on February 20, 2024.
🚩 Red Flags
- Equity financing via 'commitments' rather than a completed offering may indicate urgent need for liquidity.
📋 Key Facts
- Received commitments for $3,000,000 in additional equity.
- Expected closing date for the transaction is Tuesday, February 20, 2024.
- The filing was made under Item 8.01 (Other Events).
Renovaro Inc. (formerly Renovaro Biosciences Inc.) has consummated the acquisition of GEDi Cube Intl Ltd., making it a wholly-owned subsidiary. The transaction involved a significant issuance of unregistered common stock, resulting in the Sellers holding approximately 49% of the company's total outstanding shares.
🚩 Red Flags
- Significant dilution: The issuance of over 70 million unregistered shares significantly increases the share count and dilutes existing shareholders.
- Concentrated ownership: Sellers of the acquired entity now control nearly half (49%) of the company's equity.
- Unregistered securities: Large block of restricted stock issued via private offering exemptions rather than a registered offering.
📋 Key Facts
- Closing Date: February 13, 2024.
- The Company acquired all issued and outstanding equity interests of GEDi Cube Intl Ltd.
- Sellers received a combination of Closing Consideration (70,834,183 shares) and Earnout Shares.
- Post-transaction total Common Stock outstanding: 143,668,372 shares.
- The Sellers now hold approximately 49% of the Company's issued and outstanding common stock.
- Series A Convertible Preferred Stock was automatically converted into 5,610,100 shares of Common Stock upon closing.
- Company changed its name from Renovaro Biosciences Inc. to Renovaro Inc.
Renovaro Biosciences Inc. filed an amendment to its Certificate of Incorporation to significantly increase the number of authorized shares. This move was approved by stockholders on January 25, 2024.
🚩 Red Flags
- Massive increase in authorized share count (over 3x) often precedes significant equity dilution via new stock offerings or warrants.
📋 Key Facts
- Total authorized shares increased from 110,000,000 to 360,000,000.
- Common stock authorized shares increased from 100,000,000 to 350,000,000.
- The amendment was approved by stockholders at a special meeting on January 25, 2024.
- Effective date of the Authorized Share Amendment is February 1, 2024.
Renovaro Biosciences Inc. held a special meeting of stockholders on January 25, 2024, where shareholders approved several critical proposals related to a pending stock purchase agreement and significant increases in authorized share capital.
🚩 Red Flags
- Massive expansion of authorized share capital (from 110M to 360M) indicates significant potential dilution for existing shareholders.
- Approval of option price adjustments suggests a significant drop in stock price since original grants, necessitating downward adjustments to maintain incentive value.
📋 Key Facts
- Stockholders approved the issuance of Common Stock pursuant to a Stock Purchase Agreement dated September 28, 2023 (Proposal 1).
- Authorized shares were increased from 110 million to 360 million total, with common stock increasing from 100 million to 350 million (Proposal 2).
- Stockholders approved a decrease in the exercise price of outstanding employee/consultant stock options that were out-of-the-money (Proposal 3).
- The 2023 Equity Incentive Plan was amended to increase available shares by 5,000,000 (Proposal 4).
- A quorum was reached with approximately 46.12% of voting power represented at the meeting.
Renovaro Biosciences issued a supplemental disclosure to its proxy statement following demand letters from stockholders alleging material omissions. The supplement clarifies potential conflicts of interest involving Dr. Dybul and provides details on the background of the proposed acquisition of GEDi Cube Intl Ltd.
🚩 Red Flags
- Shareholder litigation risk: 10 purported stockholders sent demand letters and a draft unfiled complaint alleging material omissions.
- Governance concerns: The Board waived a requirement for a formal fairness opinion on the transaction valuation.
- Valuation skepticism: The Board explicitly ignored a $225M valuation report because it was based on only one prior market transaction and lacked revenue projections.
📋 Key Facts
- Stockholders sent demand letters alleging Renovaro omitted or misstated material information in the Proxy Statement regarding a transaction with GEDi Cube Intl Ltd.
- The company is voluntarily amending its Proxy Statement to avoid legal costs and delays, while denying any wrongdoing or liability.
- Dr. Dybul advised the Board on the potential opportunity with GEDi Cube, including technology and strategic rationale.
- A valuation report for GEDi Cube estimated a value of $225 million, but Renovaro's Board stated they gave no weight to it as GEDi had no revenue or projections.
- The Board directed management to waive the closing condition requiring an investment bank fairness opinion due to the lack of financial projections from GEDi Cube.
Renovaro Biosciences Inc. filed an 8-K to furnish a shareholder letter and an investor presentation dated January 16, 2024. The filing does not contain specific material financial changes or structural shifts in this cover page.
📋 Key Facts
- Company published a letter to shareholders on January 16, 2024 (Exhibit 99.1).
- Company made an investor presentation available on its website (Exhibit 99.2).
- The information in Exhibits 99.1 and 99.2 is furnished but not filed for purposes of Section 18 of the Exchange Act.